Forte Biosciences Q2 net loss $0.96/share; $106.1M cash; three FB102 trials on track for 2026 data

Forte Biosciences, Inc.

2025-Q2 EPS reported -$2.32

Net loss per share $(0.96) vs $(6.78) YoY; R&D expenses $8.6M up from $5.7M driven by clinical trials.
Cash and cash equivalents $106.1M; raised $69.9M net in June 2025 offering plus $1.7M overallotment.
Phase 2 celiac disease trial dosing; topline data expected 2026; phase 1b vitiligo data 1H26; alopecia areata initiated with 2026 data.
Shares outstanding: 12.3M common stock and 5.4M pre-funded warrants as of June 30, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.